KLOW Blend vs GLOW Blend
Quick Answer
One peptide separates them, and it is KPV. GLOW is a three-component blend of GHK-Cu, BPC-157 and TB-500. KLOW is those same three plus KPV (Lys-Pro-Val, CAS 67727-97-3, 342.43 Da), the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. KPV brings NF-kappaB-directed anti-inflammatory activity that none of the other three provide. Neither blend has ever been tested as a blend in a published study.
KLOW Blend vs GLOW Blend: At a Glance
| Attribute | KLOW Blend | GLOW Blend |
|---|---|---|
| Components | KPV, GHK-Cu, BPC-157, TB-500 | GHK-Cu, BPC-157, TB-500 |
| Component count | 4 peptides | 3 peptides |
| Added compound | KPV (Lys-Pro-Val), CAS 67727-97-3, C16H30N4O4, 342.43 Da | None — GLOW is the strict subset |
| Anti-inflammatory mechanism | Two arms: GHK-Cu antioxidant activity plus KPV NF-kappaB suppression | One arm: GHK-Cu antioxidant activity |
| Gut-barrier relevance | BPC-157 mucosal models plus KPV intestinal epithelial cytokine models | BPC-157 mucosal models only |
| Collagen and matrix remodeling | GHK-Cu — Type I and III collagen, MMP-1/2/9 in dermal fibroblast models | GHK-Cu — Type I and III collagen, MMP-1/2/9 in dermal fibroblast models |
| Local angiogenesis | BPC-157 — VEGFR2 pathway effects reported in rodent models | BPC-157 — VEGFR2 pathway effects reported in rodent models |
| Systemic cell migration | TB-500 — G-actin sequestration via the LKKTET motif | TB-500 — G-actin sequestration via the LKKTET motif |
| Component identity verification | KPV, BPC-157 confirmed against public registry records; GHK-Cu and TB-500 carry the caveats noted below | BPC-157 confirmed against public registry records; GHK-Cu and TB-500 carry the caveats noted below |
| Published study of the finished blend | None | None |
| Purity (Peptide.Express) | ≥99% per component by reverse-phase HPLC, plus compositional ratio check | ≥99% per component by reverse-phase HPLC, plus compositional ratio check |
How KLOW Blend and GLOW Blend Differ in Research
These are not rival formulations. GLOW is a strict subset of KLOW, so every mechanism present in one is present in the other and the comparison collapses to a single question: does adding KPV change the readout in the model you are running?
KPV is the cleanest component to describe because its identity is unambiguous. It is residues 11-13 of alpha-melanocyte-stimulating hormone — lysine, proline, valine — with CAS 67727-97-3, formula C16H30N4O4 and a mass of 342.43 Da. In intestinal epithelial and macrophage models it reduces pro-inflammatory cytokine output by interfering with NF-kappaB nuclear translocation, and it does so without the melanocortin receptor agonism that makes full-length alpha-MSH a pigmentation compound. That mechanism has no counterpart in the other three peptides.
The other components deserve more honesty than blend pages usually give them. BPC-157 is well pinned down: CAS 137525-51-0, C62H98N16O22, 1,419.5 Da, sequence GEPPPGKPADDAGLV. GHK-Cu is messier — it is a copper coordination complex rather than a simple peptide, no CAS number resolves cleanly to it in the reference records we verify against, and the PubChem entry for the complex (CID 139035031, C14H21CuN6O4-, 400.9 Da) describes an anionic species, which is why quoted masses for GHK-Cu differ by a few daltons between sources. TB-500 is worse: the name is used commercially for full-length synthetic Thymosin β-4 (4,963.4 Da) and in chemical registries for the Ac-LKKTETQ heptapeptide (CAS 885340-08-9, 889.0 Da). The material in these blends is the full-length protein. Check the Certificate of Analysis mass rather than trusting the name.
The comparison has one unavoidable weakness and it should be stated rather than hidden. No published study has tested the four-component blend against the three-component blend, and no published study has tested either blend at all. Everything asserted about what KPV adds here is inferred from single-compound literature. For a design where inflammation is the endpoint, KLOW offers two mechanistically independent anti-inflammatory arms. For a design where inflammation is a confounder and repair kinetics are the endpoint, GLOW has one fewer variable, and fewer variables is a real advantage when you need to attribute an effect.
Frequently Asked Questions
What is the difference between GLOW and KLOW peptides?
KPV, and nothing else. GLOW contains GHK-Cu, BPC-157 and TB-500. KLOW contains those same three plus KPV (Lys-Pro-Val), a 342.43 Da tripeptide derived from alpha-MSH with CAS 67727-97-3. GLOW is a strict subset of KLOW.
What is in KLOW blend?
Four peptides: KPV (Lys-Pro-Val, CAS 67727-97-3, 342.43 Da), GHK-Cu (a glycyl-L-histidyl-L-lysine copper complex, roughly 400 Da depending on the species recorded), BPC-157 (GEPPPGKPADDAGLV, CAS 137525-51-0, 1,419.5 Da) and TB-500 supplied as full-length synthetic Thymosin β-4 (CAS 77591-33-4, 4,963.4 Da).
What is in GLOW blend?
Three peptides: GHK-Cu, BPC-157 and TB-500 — the same three that make up three quarters of KLOW. GLOW is the earlier formulation and KLOW is its four-component extension, not a replacement or a reformulation.
Is KLOW better than GLOW?
Neither is better in the abstract, and no published study has compared them. KLOW is broader; GLOW is simpler. Any claim that the fourth component improves a specific outcome is inference from single-compound papers, not a measured result. For mechanism attribution, the formulation with fewer variables is the more useful tool.
What does KPV do that the other three components do not?
It suppresses NF-kappaB nuclear translocation, which is mechanistically distinct from GHK-Cu's antioxidant activity — the only other anti-inflammatory arm in either blend. KPV is also the only component with a dedicated intestinal epithelial cytokine literature behind it. It has no receptor overlap with the other three.
Can GLOW and KLOW be studied in the same experiment?
That is the cleanest available design, and it is what the comparison is really asking for. Because the two blends differ by exactly one peptide, running both arms isolates the KPV contribution directly instead of inferring it from separate single-compound papers. Nobody has published that experiment yet.
How much published research exists on these blends?
On the blends themselves, none. Every component has its own preclinical literature, but no peer-reviewed study has tested GLOW or KLOW as a formulation, and no study has established whether four peptides in one vial interact, compete or simply coexist. That gap is the honest ceiling on what can be claimed for either.
Are both blends the same purity?
Yes. Every component in both formulations is independently verified at ≥99% purity by reverse-phase HPLC with LC-MS/MS mass confirmation before blending, and the finished vial receives a compositional ratio check. All material is for in-vitro laboratory research use only.
References
- Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences, 2018. Read the GHK-Cu regenerative gene-data review on PMC
- Pickart L, Vasquez-Soltero JM, Margolina A. "The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging." Oxidative Medicine and Cellular Longevity, 2012. Read the GHK-Cu oxidative stress review on PMC
- Narrative review of BPC-157 for musculoskeletal healing, covering the VEGF and focal adhesion kinase mechanisms and the limits of the current evidence base. Biomolecules, 2025. Read the BPC-157 musculoskeletal healing review on PMC
- Goldstein AL, Hannappel E, Kleinman HK. "Thymosin Beta4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues." Trends in Molecular Medicine, 2005. Read the thymosin β4 actin-sequestration and tissue-repair review on PubMed
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D. "PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation." Gastroenterology, 2008. Read the KPV NF-κB and intestinal-inflammation study on PMC
Explore More
How This Page Is Sourced
Compiled by the Peptide.Express Research Team. Reviewed by Ben Laythee, Lead Chemist. Molecular identity on this page — name, CAS number, molecular formula and molecular weight — is resolved from a single internal entity record and checked against primary registries (PubChem, CAS Common Chemistry) rather than retyped per page. A field with no verified value is left out instead of estimated. Literature is cited to a DOI, PMID or PMCID permalink so every reference resolves to the specific record it names.